Actively Recruiting
Comparing Pitavastatin Alone or with Ezetimibe to Atorvastatin for Glucose Metabolism in Patients with Atherosclerotic Cardiovascular Disease and Metabolic Syndrome
Led by Yonsei University · Updated on 2026-07-07
250
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating how pitavastatin alone or combined with ezetimibe affects glucose metabolism compared to atorvastatin in patients who have both atherosclerotic cardiovascular disease and metabolic syndrome but do not have diabetes. This study aims to better understand the impact of these treatments on insulin resistance and related metabolic factors in this patient group. Participants are randomly assigned to one of three groups one receiving pitavastatin 4 mg, another receiving pitavastatin 4 mg combined with ezetimibe 10 mg, and a third receiving atorvastatin 40 mg. The treatments are given over a period of 24 weeks to compare their effects on glucose metabolism and cholesterol levels. During the study, participants will be monitored for changes in insulin resistance using the homeostatic model assessment for insulin resistance HOMA-IR, fasting glucose, HbA1c, and lipid profiles. Researchers will assess these outcomes at the 24-week mark to evaluate the treatments impact. Safety and adherence will be monitored throughout, and the total participation duration is approximately 24 weeks.
CONDITIONS
Brief Title
Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial
Research Team
B
Byeong-Keuk Kim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
